Portfolio

Peer-reviewed research, clinical-AI deployment in community behavioural health, and projects across health equity, primary care, and access.

Publications & patents

My research turns speech into an objective, scalable signal for detecting serious mental illness. It began in medical school, with work on machine learning for diagnosing and enabling early intervention in schizophrenia: the non-imaging biomarker research that led me to found Psyrin. It has produced a peer-reviewed study in Translational Psychiatry showing serious mental illness can be detected from five minutes of remotely collected speech, and a published UK patent covering the method.

Reliable mental-health assessment is scarcest exactly where it is needed most. A brief, objective, remotely administered speech test points toward screening that can scale into under-resourced US settings. That access problem sits at the centre of my work.

Detecting schizophrenia, bipolar disorder, psychosis vulnerability and major depressive disorder from 5 minutes of online-collected speech

Julianna Oláh, Win Lee Edwin Wong, Atta-ul Raheem Rana Chaudhry, Omar Mena, Sunny X. Tang

Translational Psychiatry · July 2025 · doi: 10.1038/s41398-025-03433-0

From five minutes of online-collected speech, a fully automated machine-learning pipeline distinguished serious mental illness from healthy controls with 86% accuracy (AUC 0.91), and classified across the schizophrenia–bipolar spectrum, major depressive disorder, and sub-clinical psychotic experiences (N≈1,140). The work introduces a standardised, remotely deployable protocol for multi-illness speech-based screening, addressing the small samples and single-illness scope that had limited earlier work.

Read the paper

Published as Atta-ul Raheem Rana Chaudhry, the full form of Raheem Chaudhry.

Vocal Assessment

Julianna Oláh, Atta-ul Raheem Rana Chaudhry, Win Lee Edwin Wong

UK patent · GB2635194A (application GB2316813.1) · Assignee: Psyrin Ltd · Filed Nov 2023 · Published May 2025

A method for assessing mental characteristics (including depression, schizophrenia, bipolar disorder, and psychosis risk) from a person's speech, analysing semantic coherence, connectivity graphs, syntax, and acoustic features to help guide treatment selection.

View the patent

Work

Getting clinical AI to work inside the US community behavioural-health services that serve the highest-need patients with the fewest resources. The constraints are staffing, funding, and workflow, not the model.

Deploying Mira across community behavioural health

Psyrin · multi-site, United States

Mira is our conversational clinical AI, built with strict clinical guardrails. At Psyrin I lead her deployment into multi-site community behavioural-health organisations in the United States, translating clinical complexity into operational reality: fitting AI to existing intake and documentation workflows, the staff who run them, and the payor constraints they work under. Feedback from the patients and staff who use her has been consistently strong. In July 2026 this work reached state level with the launch of RecoveryRachel, an AI navigation platform built with RecoveryOhio to help Ohioans find mental-health and addiction treatment.

View the case study RecoveryRachel launch announcement

Clinical trials: taking the speech-biomarker method into US studies

Psyrin · ClinicalTrials.gov · United States

I am a Principal Investigator on MINDAIM (NCT06792175), a prospective observational study of speech-based machine-learning assessment and risk stratification in around 500 participants, run in real community behavioural-health settings with Allwell Behavioral Health Services in Ohio and The Brookline Center in Massachusetts. I also support Psyrin's study of speech as a predictor of treatment response to psychiatric interventions (NCT06823024), and the wider research programme including the PRIME relapse-forecasting and CHRONOS-AI studies.

MINDAIM (NCT06792175)Treatment-response study (NCT06823024)Psyrin research

AI-consults field study

Community behavioural health clinics

Before and during rollout I sat in multiple community behavioural-health clinics to see how care is actually delivered and where AI helps versus gets in the way. That fieldwork, watching real intake, documentation, and hand-offs, shapes how we build and where we deploy. At deployment sites I also built and delivered the clinical and staff training that gets Mira into daily use.

Voice biomarker pipeline, voice agents, and the Psyrin website

Psyrin · technical work

I designed Psyrin's early voice-biomarker pipeline and analysis: the path from the schizophrenia-from-speech research to a working product pipeline that underpins the published work. I've kept building since, including voice agents for the business (customer support among them) and the Psyrin website.

Early regulatory groundwork with the FDA

Psyrin · regulatory strategy

I led Psyrin's early regulatory work, including applications to the FDA, before we made the strategic decision to defer the regulatory path until after Mira's release. (Early groundwork and submissions, not a clearance or active filing.)

Projects

The same thread of widening access and improving care for underserved and marginalised groups, in different settings: health equity, behavioural health in primary care, and care for asylum seekers. Plus the biomedical research where the scientific training began.

Equality & inclusion

Gender identity, disability, and mental health

King's College London

A sustained strand of work on equality in health: a student-selected project on disability and gender identity in children, teaching peers on trans healthcare, and serving as a panellist at an LGBT Schwartz Round.

Primary care

Pre-screening for colorectal cancer in diabetic patients

Quality Improvement Project · Springfield Medical Centre

Built a pre-screening tool to flag colorectal-cancer symptoms within the diabetes population in primary care.

Access & equity

Multilingual health support for asylum seekers

KCL LEADER project · Health Inclusion Team, St Thomas'

Built ready-to-send, human-translated (Doctors of the World) NHS-navigation and wellbeing resources in 12 languages, delivered by text to asylum seekers through a hospital inclusion clinic and a Clapham GP practice.

Biomedical research

Hyperinsulinaemia and bone mineral density in PCOS

BSc Biomedical Science, Cardiff University (1st Class)

Final-year research investigating the role of hyperinsulinaemia on bone mineral density in polycystic ovary syndrome.

Talks & media

Selected talks, profiles, and conversations about the work.

Invited talk — RCPsych Digital Psychiatry SIG conference, “Digital Futures!”
Royal College of Psychiatrists, London · 4 September 2023
Returned as the previous year's presentation-prize winner to present Psyrin's progress.
Conference programme (PDF) →
Panel — Digital Health AI and Data conference: “AI-powered decision support for clinicians”
London · 31 October 2023
Panellist on integrating AI and data analytics into clinical workflows, alongside founders and clinical leads from across UK digital health.
Session page →
Profile — The Frontier Psychiatrists: “Psyrin and the Future of Vocal Biomarkers”
Owen Scott Muir, M.D. · September 2024
An in-depth profile of Psyrin's speech-biomarker work, including an extended interview on the path from NHS practice to building the company.
Read the profile →
Podcast — The Blue Payphone: “Disrupting Psychosis Care with Speech and AI — The Psyrin Journey”
Episode 14 · April 2023
A conversation with Psyrin's three co-founders on early detection in psychosis care and why they started the company.
Listen on Spotify →